TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms

Journal of Clinical Oncology

Volumn 21, Issue 24, 2003, Pages 4505-4509

  Nichols, Kim E ^a   Heath, John A ^a   Friedman, Debra ^a   Biegel, Jaclyn A ^a   Ganguly, Arupa ^a   Mauch, Peter ^a   Diller, Lisa ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER SURVIVOR; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FAMILY HISTORY; GENE MUTATION; HODGKIN DISEASE; HOMOZYGOSITY; HUMAN; PRIORITY JOURNAL; SECOND CANCER; TUMOR SUPPRESSOR GENE; ADULT; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

ADULT; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY;

EID: 1542438635     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.042     Document Type: Article

References (41)

1. Mauch PM: Controversies in the management of early stage Hodgkin's disease. Blood 83:318-329, 1994
2. Mauch PM, Kalish LA, Marcus KC, et al: Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome. Blood 87:3625-3632, 1996
3. Doria R, Holford T, Farber LR, et al: Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 13:2016-2022, 1995
4. Ng AK, Bernardo MV, Weller E, et al: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100:1989-1996, 2002
5. Dores GM, Metayer C, Curtis RE, et al: Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 20:3484-3494, 2002
6. Bhatia S, Robison LL, Oberlin O, et al: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745-751, 1996
7. Donaldson SS, Hancock SL: Second cancers after Hodgkin's disease in childhood. N Engl J Med 334:792-794, 1996
8. Wolden SL, Lamborn KR, Cleary SF, et al: Second cancers following pediatric Hodgkin's disease. J Clin Oncol 16:536-544, 1998
9. Moppett J, Oakhill A, Duncan AW: Second malignancies in children: The usual suspects? Eur J Radiol 37:95-108, 2001
10. Bhatia S, Louie AD, Bhatia R, et al: Solid cancers after bone marrow transplantation. J Clin Oncol 19:464-471, 2001
11. Nichols KE, Levitz S, Shannon KE, et al: Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol 17:1259-1266, 1999
12. Broeks A, Urbanus JH, Floore AN, et al: ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet 66:494-500, 2000
13. Li FP, Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome? Ann Intern Med 71:747-752, 1969
14. Diller L, Kassel J, Nelson CE, et al: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772-5781, 1990
15. Hisada M, Garber JE, Fung CY, et al: Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90:606-611, 1998
16. Malkin D, Jolly KW, Barbier N, et al: Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326:1309-1315, 1992
17. Nichols KE, Malkin D, Garber JE, et al: Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10:83-87, 2001
18. Liu Y, West SC: Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res 4:9-13, 2002
19. Sharan SK, Morimatsu M, Albrecht U, et al: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804-810, 1997
20. Gowen LC, Avrutskaya AV, Latour AM, et al: BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281:1009-1012, 1998
21. Abbott DW, Freeman ML, Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90:978-985, 1998
22. The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers: The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310-1316, 1999
23. Easton DF, Steele L, Fields P, et al: Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 61:120-128, 1997
24. Johannsson O, Loman N, Moller T, et al: Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 35:1248-1257, 1999
25. Shih HA, Nathanson KL, Seal S, et al: BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 6:4259-4264, 2000
26. Tonin P, Ghadirian P, Phelan C, et al: A large multisite cancer family is linked to BRCA2. J Med Genet 32:982-984, 1995
27. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, et al: IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines-International Agency for Research on Cancer. Hum Mutat 14:1-8, 1999
28. National Human Genome Research Institute: Breast cancer information core database. http://www.research.nhgri.nih.gov/bic/
29. Birch JM, Hartley AL, Tricker KJ, et al: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298-1304, 1994
30. Thomas M, Kalita A, Labrecque S, et al: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092-1100, 1999
31. Dumont P, Leu JI, Della Pietra AC, et al: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365, 2003
32. Cho Y, Gorina S, Jeffrey PD, et al: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355, 1994
33. Whiteside D, McLeod R, Graham G, et al: A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple cafe-au-lait spots. Cancer Res 62:359-362, 2002
34. Storey A, Thomas M, Kalita A, et al: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393:229-234, 1998
35. Hildesheim A, Schiffman M, Brinton LA, et al: p53 polymorphism and risk of cervical cancer. Nature 396:531-532, 1998
36. Ara S, Lee PS, Hansen MF, et al: Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 18:4961, 1990
37. Olschwang S, Laurent-Puig P, Vassal A, et al: Characterization of a frequent polymorphism in the coding sequence of the TP53 gene in colonic cancer patients and a control population. Hum Genet 86:369-370, 1991
38. Futreal PA, Liu Q, Shattuck-Eidens D, et al: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122, 1994
39. Lancaster JM, Wooster R, Mangion J, et al: BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13:238-240, 1996
40. Teng DH, Bogden R, Mitchell J, et al: Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 13:241-244, 1996
41. Gaffney DK, Hemmersmeier J, Holden J, et al: Breast cancer after mantle irradiation for Hodgkin's disease: Correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2. Int J Radiat Oncol Biol Phys 49:539-546, 2001